With operations across 50 countries, MagicLab is pairing new robot systems with a platform strategy aimed at wider commercial adoption
Updated
May 1, 2026 2:16 PM
.jpg)
A standing yellow robotic arm. PHOTO: UNSPLASH
MagicLab Robotics is a Chinese startup that describes itself as an embodied AI company. At an event in Silicon Valley this week, it outlined its global ambitions and introduced new products designed for real-world use. The company said its international business now spans more than 50 countries and regions, with overseas markets accounting for 60% of total sales in 2025. That gives some indication of how quickly Chinese robotics firms are expanding beyond their home market.
At the centre of the announcement was MagicLab’s latest product line-up. It included Magic-Mix, described as a foundational world model for robots, the H01 dexterous robotic hand and its humanoid robot, MagicBot X1. In practical terms, the company is trying to build robots that can better understand their surroundings and perform physical tasks with greater precision. That is the core idea behind embodied AI, where intelligence is combined with movement and interaction in the real world rather than limited to software alone.
MagicLab says it develops both hardware and software internally. Its product range includes humanoid robots and four-legged machines, with systems designed for factories, commercial services and home use. The company also outlined where it sees demand emerging. It listed sectors such as healthcare, manufacturing, logistics, security, public safety, education and household assistance.
That wide spread of target markets reflects a broader challenge in robotics. Building capable machines is only one part of the equation. The harder task is finding enough practical uses where customers are willing to pay for them.
MagicLab also used the summit to set out a long-term commercial goal. It projected a path toward US$14 billion in annual revenue by 2036 through wider adoption of embodied AI systems. It also announced what it calls the “Co-Create 1000 Initiative”, a plan to work with external developers and partner companies.
As part of that effort, the startup said it plans to invest US$1 billion over the next five years to build a developer ecosystem that would allow third parties to create new applications for its robots. The strategy mirrors what happened in smartphones and cloud software, where ecosystems often mattered as much as the original hardware. If robotics follows a similar path, companies that attract developers could gain an advantage over those selling machines alone.
For now, MagicLab’s announcement is less about immediate breakthroughs and more about positioning. The company is presenting itself not simply as a robot maker, but as a platform business seeking a role in the next phase of intelligent machines.
Keep Reading
A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
May 1, 2026 2:25 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.